Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Indivior PLC (INDV : NSDQ)

• Company Description    Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. Number of Employees: 1,051

• Price / Volume Information    Yesterday's Closing Price: $23.88 Daily Weekly Monthly 20 Day Moving Average: 2,106,817 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 0.81 52 Week High: $25.10 52 Week Low: $7.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.06% 1.20% 12 Week 71.80% 55.98% Year To Date 92.12% 71.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10710 Midlothian Turnpike Suite 125 - North Chesterfield,VA 23235 USA ph: 804-379-1040 fax: 804-379-1215 investorrelations@indivior.com http://www.indivior.com

• General Corporate Information    Officers Mark Crossley - Chief Executive Officer David Wheadon - Chairman Ryan Preblick - Chief Financial Officer Woodrow Anderson - Senior Vice President Juliet Thompson - Director Peer Information Indivior PLC (GSAC) Indivior PLC (CASI) Indivior PLC (ALCD.) Indivior PLC (OMNN) Indivior PLC (CGPI.) Indivior PLC (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: G4766E116 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 10/23/25 Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: 0.81 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.72 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/23/25

• Fundamental Ratios P/E Current FY Estimate: 13.88 Trailing 12 Months: 13.42 PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: 13.12 Price / Sales: - EPS Growth vs. Year Ago Period: 15.91% vs. Previous Quarter: 24.39% Sales Growth vs. Year Ago Period: 1.00% vs. Previous Quarter: 13.53% ROE 06/30/25 - -86.28 03/31/25 - -97.29 12/31/24 - -143.13 ROA 06/30/25 - 16.26 03/31/25 - 15.74 12/31/24 - 15.53 Current Ratio 06/30/25 - 0.90 03/31/25 - 0.88 12/31/24 - 0.89 Quick Ratio 06/30/25 - 0.76 03/31/25 - 0.72 12/31/24 - 0.70 Operating Margin 06/30/25 - 19.44 03/31/25 - 19.15 12/31/24 - 18.85 Net Margin 06/30/25 - 6.65 03/31/25 - -4.02 12/31/24 - -3.96 Pre-Tax Margin 06/30/25 - 15.60 03/31/25 - 0.00 12/31/24 - 1.18 Book Value 06/30/25 - - 03/31/25 - -2.07 12/31/24 - -2.52 Inventory Turnover 06/30/25 - 1.26 03/31/25 - 1.37 12/31/24 - 1.34 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©